Menu

Image of the Day: Glucose Sensor 

Scientists build a biosensor skin patch for noninvasive glucose monitoring. 

Jan 2, 2018
The Scientist Staff, The Scientist Staff

The new biosensor, which is designed to measure blood glucose when attached to the skinXUE FENG & YIHAO CHEN, TSINGHUA UNIVERSITYDeveloping noninvasive methods of glucose monitoring is challenging, but researchers have designed a new biosensor with high measurement accuracy that can be placed directly on the skin. The device integrates a battery-powered electrochemical channel that transports intravascular blood glucose to the skin surface, and an ultrathin, nanostructured biosensor absorbs and measures the glucose.

In a human clinical trial, the measurements taken from the new sensor showed a high correlation with clinically measured blood glucose levels. 

See “Will the Noninvasive Glucose Monitoring Revolution Ever Arrive?” 

Y. Chen et al., "Skin-like biosensor system via electrochemical channels for noninvasive blood glucose monitoring," Science Advances, doi:10.1126/sciadv.1701629, 2017. 

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.